storyblocks.com
Clinical Study Results
In female patients with breast cancer, selenase® oral liquid reduced the severity of lymphedema, a painful, often debilitating side effect of cancer treatments.
selenase® oral liquid + CPDT* was compared with placebo+ + CPDT in a clinical study of 179 female patients with breast cancer and lymphedema.
In this study, patients received either selenase® oral liquid once daily (at a dose of 1000 μg in 1st week, 300 μg in 2nd and 3rd week) or placebo. All patients in the study received CPDT*.
In this clinical study:
- selenase® oral liquid + CPDT increased selenium levels in whole blood (from approximately 69 to 112 μg/l)
- selenase® oral liquid + CPDT increased the efficacy of CPDT‡ vs. females taking placebo + CPDT
- selenase® oral liquid + CPDT reduced the risk of bacterial infection vs. females taking placebo + CPDT
*Refers to combined physical decongestion therapy, an intensive program that combines physical therapy with manual or mechanical lymph drainage and compression bandaging.
+Pronounced “pluuh-see-bow”: an oral liquid that looks like “real” medicine but contains nothing to affect health.
‡Measured by the mobility and heat tolerance of the affected arm.
For more information
In selenium-deficient female patients with cervical and uterine cancer, selenase® oral liquid reduced side effects induced by radiotherapy (RT).
selenase® oral liquid was compared with placebo* in a clinical study of 81 selenium-deficient patients with cervical and uterine cancer.
In this study, patients received either selenase® oral liquid (at a dose of 500 μg on days of RT, 300 μg on days without RT) or placebo.
In this clinical study:
- selenase® oral liquid increased selenium levels in whole blood (from approximately 65 to 95 μg/l)
- selenase® oral liquid reduced RT-induced side effects+ vs. patients taking placebo
- selenase® oral liquid reduced the risk of death‡ vs. patients taking placebo even after the conclusion of the study
*Pronounced “pluuh-see-bow”: an oral liquid that looks like “real” medicine but contains nothing to affect health.
+Measured by the number of episodes and severity of RT-induced diarrhea.
‡Measured by overall survival rates.
For more information
In female patients with autoimmune thyroiditis (AIT), selenase® oral liquid helped inhibit the thyroid autoimmune response in AIT disease development.
selenase® oral liquid was compared with placebo in a clinical study of 70 patients with autoimmune thyroiditis (AIT)*.
In this study, patients received either selenase® oral liquid, at a daily dose of 200 μg, or placebo+, for 3 months.
In this clinical study:
- selenase® oral liquid significantly reduced thyroid auto-antibodies (from 88% to 63.6%).
- selenase® oral liquid improved the inflammatory activity‡ seen in autoimmune thyroiditis vs. patients taking placebo.
*All selected patients had thyroid peroxidase antibodies (TPOAb) and/or Tg antibodies (TgAb) above 350IU/ml.
+Pronounced “pluuh-see-bow”: an oral liquid that looks like “real” medicine but contains nothing to affect health.
‡Nine patients receiving selenase® oral liquid had complete normalization of antibodies and normal echogenicity of thyroid vs. two in the placebo group.
